Avanir Pharmaceuticals Inc Stock
Equities
US05348P4019
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2014 | Otsuka : Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff | RE |
2014 | NASDAQ OMX : names 14 stocks to test lower fee and rebate programme | RE |
Managers | Title | Age | Since |
---|---|---|---|
Dan Dalton
CMP | Compliance Officer | - | 16-05-31 |
Kelly Parker
IRO | Public Communications Contact | - | 15-05-31 |
Aneta Ferguson
LAW | General Counsel | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Donald Hayden
CHM | Chairman | 68 | - |
Robert McQuade
BRD | Director/Board Member | 67 | - |
Thomas DesRosier
BRD | Director/Board Member | 69 | - |
1st Jan change | Capi. | |
---|---|---|
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- Stock